Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 1.00 |
| ▸ | CA1 | P00915 | 8/20 | 0.77 |
| ▸ | CA4 | P22748 | 5/20 | 0.77 |
| ▸ | CA12 | O43570 | 4/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.77 |
| ▸ | CA5A | P35218 | 3/20 | 0.77 |
| ▸ | CA9 | Q16790 | 3/20 | 0.77 |
| ▸ | CA6 | P23280 | 2/20 | 0.77 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.77 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10924391 | 0.94 | CA2 (0.88) | CA2CA1CA4CA12CA14 | |
| SCHEMBL160105 | 0.87 | CA2 (1.00) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10348111 | 0.81 | CA2 (0.76) | CA2CA1CA4CA12CA14 | |
| SCHEMBL25862169 | 0.81 | CA2 (0.68) | CA2CA1CA4CA12CA14 | |
| SCHEMBL31452866 | 0.80 | CA2 (0.67) | CA2CA1CA4CA12CA14 | |
| SCHEMBL14317794 | 0.80 | CA2 (0.67) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10913170 | 0.76 | CA2 (0.64) | CA2CA1CA4CA12CA14 | |
| SCHEMBL14299650 | 0.76 | CA2 (0.61) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10913446 | 0.76 | CA2 (0.61) | CA2CA1CA4CA12CA14 | |
| SCHEMBL30297744 | 0.75 | CA2 (1.00) | CA2CA1CA4CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697302-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | University of Louisville Research Foundation (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005066114-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2005-06-30 | — | — | US | claimed |
| US-6313155-B1 | Composition and method for treating macular disorders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2001-11-06 | — | — | US | claimed |
| WO-2000066613-A1 | BONE TARGETING AGENTS FOR OSTEOPOROSIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-11-09 | — | — | WO | claimed |
| EP-0079269-B1 | HYDROXY-SUBSTITUTED-2-BENZOTHIAZOLESULFONAMIDE FOR THE TOPICAL TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1986-05-14 | — | — | EP | claimed |
| US-4454148-A | 5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-06-12 | — | — | US | claimed |
| EP-0079269-A1 | Hydroxy-substituted-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1983-05-18 | — | — | EP | claimed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-4454148-A | 5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4426388-A | 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-01-17 | — | — | US | disclosed |
| US-4426388-A | 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0091367-A2 | Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1983-10-12 | — | — | EP | disclosed |
| EP-0091367-A2 | Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1983-10-12 | — | — | EP | disclosed |
| EP-0079269-A1 | Hydroxy-substituted-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1983-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | CA2 1214/4885CA1 3679/4885CA4 2354/4885 |
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | SOST, BMP2, BMP4 | CA2 1902/4885CA1 2975/4885CA4 1429/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | CA2 728/4885CA1 3330/4885CA4 2017/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | CA2 600/4885CA1 1530/4885CA4 2005/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | CA2 238/4885CA1 1942/4885CA4 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.